{\rtf1 \ansi 
{\colortbl;
\red0\green0\blue0;
\red255\green255\blue255;
\red255\green0\blue0;
\red0\green255\blue0;
\red0\green0\blue255;
\red0\green255\blue255;
\red255\green0\blue255;
\red255\green255\blue0;
\red0\green0\blue128;
\red0\green128\blue128;
\red0\green128\blue0;
\red128\green0\blue128;
\red128\green0\blue0;
\red128\green128\blue0;
\red128\green128\blue128;
\red192\green192\blue192;
\red170\green170\blue170;
\red33\green33\blue33;
\red37\green37\blue37;
\red187\green187\blue187;
\red85\green85\blue85;
\red107\green107\blue106;
\red14\green86\blue140;
\red255\green255\blue102;
\red119\green119\blue119;
\red203\green203\blue203;
\red245\green245\blue245;
\red238\green238\blue238;
\red20\green93\blue164;
\red246\green246\blue246;
\red249\green250\blue251;
\red204\green204\blue204;
\red228\green231\blue232;
\red80\green80\blue80;
\red51\green51\blue51;
\red56\green124\blue43;
\red151\green151\blue151;
\red181\green79\blue104;
\red21\green137\blue21;
\red0\green114\blue54;
\red106\green144\blue39;
\red247\green247\blue247;
\red254\green254\blue0;
\red232\green233\blue232;
\red61\green61\blue61;
\red227\green227\blue227;
\red240\green240\blue240;
\red105\green105\blue105;
\red255\green248\blue96;
\red233\green233\blue233;
\red249\green249\blue249;
\red112\green112\blue112;
\red204\green255\blue255;
\red229\green243\blue255;
\red179\green218\blue255;
\red255\green255\blue174;
\red255\green255\blue204;
\red255\green204\blue0;
\red188\green41\blue30;
\red190\green237\blue228;
\red190\green190\blue252;
\red102\green102\blue102;
\red86\green86\blue86;
\red250\green250\blue250;
\red70\green70\blue70;
\red218\green218\blue218;
\red250\green222\blue100;
\red61\green61\blue60;
\red255\green128\blue0;
\red239\green122\blue2;
\red255\green194\blue211;
\red236\green236\blue236;
\red153\green153\blue153;
\red71\green120\blue194;
\red240\green248\blue255;
\red127\green127\blue127;
\red223\green223\blue223;
\red239\green239\blue239;
\red255\green255\blue198;
\red214\green214\blue214;
\red183\green242\blue206;
\red120\green162\blue47;
\red251\green252\blue255;
\red208\green208\blue208;
\red72\green72\blue72;
\red190\green195\blue204;
\red102\green0\blue102;
\red118\green118\blue118;
\red182\green231\blue243;
\red153\green255\blue102;
\red255\green210\blue183;
\red221\green195\blue236;
\red214\green9\blue9;
\red172\green172\blue172;
\red9\green56\blue84;
}
{\fonttbl {
\f0 Arial;}{
\f1 Symbol;}{
\f2 Times New Roman;}{
\f3 sans-serif;}{
\f4 georgia;}{
\f5 serif;}{
\f6 Source Sans Pro;}{
\f7 Courier New;}
}
{\*\generator Apache XML Graphics RTF Library;}
\fet0 \ftnbj 
{\*\listtable
{\list\listtemplateid7551103\listsimple{\listlevel\leveljc\levelfollow0\levelspace0\levelindent0{\leveltext\'01\u160\'3f}{\levelnumbers}}{\listname ;}\listid1432597721}
}
{\*\listoverridetable
{\*\listoverride{\listid1432597721\listoverridecount0\ls1}}
}
\paperw12240 \paperh15840 \margt1080 \margb1080 \margl1080 \margr1080 \headery720 \footery720 \itap0 \cols2 
\sectd {\header {
{\trowd \ltrrow \trleft0 
\clpadb60 \clpadfb3 \clpadl400 \clpadfl3 \clbrdrt \clbrdrb \brdrcf17 \brdrw20 \brdrs \clbrdrl \trql \clvertalb \clwWidth9380 \cellx9380 
\clpadb60 \clpadfb3 \clpadl400 \clpadfl3 \clbrdrt \clbrdrb \brdrcf17 \brdrw20 \brdrs \clbrdrr \trql \clwWidth700 \cellx10080 
\intbl 
{\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 
}
{\b1 \cf21 \f0 \i0 \fs18 
{\b1 \cf21 \f0 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
ChromaDex, Inc. v. Elysium Health, Inc., Slip Copy (2021)
}
}
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 
}
}\b0 \cf1 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs18 \li0 \sa0 \sb0 \intbl \cell \intbl 
{\qr \b0 \cf1 \f0 \ri0 \i0 \fs18 \li0 
}\qr \b0 \cf1 \f0 \ri0 \i0 \fs18 \li0 \intbl \cell \row }
{\trowd \lastrow \trleft0 
\clbrdrb \clbrdrl \trql \clwWidth10080 \cellx10080 
\intbl 
{\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 
}\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 \intbl \cell \row }}\par }{\footer {
{\trowd \lastrow \trleft0 
\clpadl60 \clpadfl3 \clbrdrt \brdrcf17 \brdrw20 \brdrs \clbrdrb \clbrdrl \trql \clvertalb \clwWidth9300 \cellx9300 
\clpadl60 \clpadfl3 \clbrdrt \brdrcf17 \brdrw20 \brdrs \clbrdrb \clbrdrr \trql \clwWidth700 \cellx10000 
\intbl 
{\b0 \cf17 \f0 \ri0 \i0 \ql \fs20 \li0 
{\b0 \cf17 \f0 \ul0 \strike0 \i0 \fs20 
}
{\*\shppict {\pict \pngblip \picw78 \pich10 \picwgoal1170 \pichgoal150 89504e470d0a1a0a0000000d494844520000004e0000000a08030000002dbd985500000300504c5445f8a969f6913ff68931fff9f5f69241f5852af68d38fcddc4f58326fac294f8a868fac193fcdabefab985fcdfc7fef5eef58022f8a35efef6effde5d2fac092fffaf6f9ac6ffffcfafde8d7fef7f1f9b279f6862cf8aa6af79e56f79c53f58327fef1e7fde3cefeeee2f9b076f79a4efef8f4f58123f58224f9ae72feefe4f58021f9ae71fac295fffaf7fcdabffef7f2f9af73f9b177f8ac6ef9b47cf8a15bf6872ef79648fef5edf9b278fcd9bdf9b782f9b57efbc89ffde3cffffefdf6872df8aa6bfcd6b8fac59af9b781fabc8bfffbf8fac091fac396fbceaaf8a461f68e39f6882ffabe8dfabf8ff9b884f79c52fdeadbfeede0f68c36f89f58fcdcc3fde0c9fef0e5fef3eaf68f3cfbcaa2f8a867f9b37afaba87f68b35fde7d6fabf90fffcfbfaba86fde7d5f6903efffdfcfef4ecf68f3bfde1cafcdfc6fbd1affbcea9fcd6b7f68a33f79444fbcba5f58429fcdec6f9af74f8a25df58428f7a461fef4edfdede0fde6d4fde7d4f9b680fbc69cfbc8a0f9b37bfac9a1f69240f79d54fcd4b4f9b883f68e3afef8f3fdebddfde2cbf7984cf8a35ff6882efef3ebf9bd8cfcd4b5feecdef8a562fde6d3fef9f4fcdbc1f9bc8afcd8bcf8ab6dfef8f2fcd7b9fffbf7feefe3f79546f8aa69f79f57fde1cbfcd3b3fcd2b1f8a25cfcd3b2fde2ccfac599fac397f9b379fcd8bbfbd2b0fef2e9fcd5b6fac79ef8a664f8a460f68a32fac090fffbf9fef2e8f8ab6cfde4d0f7994df6903df79749fffefcf79e55f8a766f8a059f68830f7974afde2cdfbcca6fabd8cf57f20ffffff000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000c5baaa8e000000bf74524e53ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff00456e8439000002804944415478da63dcc70001fef2931866b0be0cd2085114e5ff7ef72a0357d0a3a31cc2129ebb9f492a3e4b6eb8cb20913bb5c808a2f849bf610c438bf99a9917cf2a18092c7bf1a30a6a0a13946658f6af92e15352e52386af5d677ee5ff61618c5ca7c6b58921d6ecc47383e56a52b3181955bf2e3e01513b49bae7260383be8b048376a2e34786a3853761a6b0c018892b57313c48fa38834195c1cf94c16a3a03c3edad7c5f163030a8672bcc3afcf4251343639ef3ae2cb05afe384e9390352a0c320cbdf71f19b43d6690c7302e84e11383d28bff67bcba9a6e2831acd9c6e0d990fe70b74ae7d2a90c0cbbc36fbaef6660b80f55ba68e9d2d5a9ae0cdd2f341878be8b9c64f8cb701d660a733c9451af78704effa1c6b3536708cf2c9ffde7c78fcb9b16497b8acf3e3721061812bfde8433302c8d5a190152ca93f7d26df6796bff83310dbfe504de7f7ff9ec621c7ad8ade964d5f0f8162da4257e9da18c39434955602283a37fdaefde9cb30c686005c3a4c9a6d792186c6b665d8e54f97ae7c5badd189e65307c22395565fbc43fcc010cad5b3ba781c5363184af0bfa8530481844b84e65b87efde6bcb50c67d9dc36d4f6bf7aa6e4015700771dc3fd57751f183c97ecfe7f04c8b17e9f9fdfceb0e334c3ca37c16940feb644b09ad7e1aee90cdaaa9f1ca31ef6bd6478e2b43ba29f615fc7cf550c1861c720c2699619c930d362d55a060ff68e592f7d4eacd82df9eb3bd7bd387986ff73182d18183686ba2ff9f76ec59f909c2e83a8499dbbaaa404ecf8199cb8051e79627ad6fa4799360383602cd0bdcbdeb2fc6158debec577daf1a9076ba51818e679bf05aaf85cfdeb0f8383c1ec0973801cee342386c537cdf218fecf4b70801b0200f61ff095f54de6170000000049454e44ae426082}}
{\b0 \cf17 \f0 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u169\'3f 2021 Thomson Reuters. No claim to original U.S. Government Works.
}
}\b0 \cf17 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs20 \li0 \sa0 \sb0 \intbl \cell \intbl 
{\qr \b0 \cf17 \f0 \ri0 \i0 \fs20 \li0 
{\b0 \i0 \ul0 \fs20 \f0 \chpgn }
}\qr \b0 \cf17 \f0 \ri0 \ul0 \strike0 \i0 \fs20 \li0 \intbl \cell \row }}\par }
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_document_26}{\*\bkmkend co_document_26}
{\b0 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart I434851301b7111ec8b1bdba4dd95a23d_Target}{\*\bkmkend I434851301b7111ec8b1bdba4dd95a23d_Target}
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\*\bkmkstart co_readingModeKC_26}{\*\bkmkend co_readingModeKC_26}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\*\bkmkstart co_readingModeCitatorFlag_26}{\*\bkmkend co_readingModeCitatorFlag_26}
{\b0 \cf1 \f2 \i0 \fs16 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/RelatedInformation/Flag?documentGuid=I434851301b7111ec8b1bdba4dd95a23d&transitionType=Document&originationContext=docHeaderFlag&Rank=0&rs=cblt1.0&vr=3.0&contextData=(sc.Search)" }{\fldrslt 
{\*\shppict {\pict \pngblip \picw16 \pich16 \picwgoal255 \pichgoal255 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}}}}
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
KeyCite Blue Flag \u8211\'3f Appeal Notification
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\*\bkmkstart co_readingModeNegativeTreatment_26}{\*\bkmkend co_readingModeNegativeTreatment_26}
{\b0 \cf1 \f2 \i0 \fs16 {\fi-360 \li {\*\pn \pnlvlblt \ilvl0 \ls1 \pnindent0 \pnf1 {\f2 \pntxtb \u160\'3f}}{\listtext \b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 \u160\'3f\tab }\ls1 {\pntext }
{\pard }\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
Appeal Filed by 
}
}
{\field {\*\fldinst HYPERLINK "https://www.westlaw.com/Document/I5CE3710C3D0211ECBE4EDDCDD34AD981/View/FullText.html?navigationPath=RelatedInfo%2Fv4%2Fkeycite%2Fnav%2F%3ForigDocGuid%3DI434851301b7111ec8b1bdba4dd95a23d&listSource=RelatedInfo&list=NegativeCitingReferences&rank=0&ppcid=b360031fa5894f02ba28ce2a4616d4d6&originationContext=docHeader&transitionType=NegativeTreatment&contextData=%28sc.Search%29&VR=3.0&RS=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
CHROMADEX, INC. v. ELYSIUM HEALTH, INC.
}
{\b0 \cf23 \f2 \i0 \fs16 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
, 
}
}}}
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
Fed.Cir., 
}
}
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
November 3, 2021
\par {\pntext }
}
}
}
}
}
}
}
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
2021 WL 4286527
\par 
}
}
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Only the Westlaw citation is currently available.
\par 
}
}
}
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
United States District Court, D. Delaware.
\par 
}
}
}
{\b0 \qc \cf19 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \qc \cf19 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \qc \cf19 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
CHROMADEX, INC. and Trustees of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Search/Results.html?query=advanced%3a+WCAID(I51F02C30621311E080258F0E01953BF2)&saveJuris=False&contentType=BUSINESS-INVESTIGATOR&startIndex=1&contextData=(sc.Default)&categoryPageUrl=Home%2fCompanyInvestigator&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem" }{\fldrslt 
{\b0 \cf23 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
Dartmouth College
}}}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb240 
 Plaintiffs,
\par 
}
}
{\b0 \qc \cf19 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
v.
\par 
}
}
{\b0 \qc \cf19 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa240 \sb0 
ELYSIUM HEALTH, INC. Defendant.
\par 
}
}
}
}
{\b0 \qc \cf1 \f2 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Civil Action No. 18-1434-CFC-JLH
\par 
}
}
}
{\b0 \cf1 \f4 \i0 \fs20 
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
|
\par 
}
}
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa200 \sb0 
Signed 09/21/2021
\par 
}
}
}
}
{\b1 \cf18 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_attorneysAndLawFirms_26}{\*\bkmkend co_attorneysAndLawFirms_26}
{\b1 \cf18 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
Attorneys and Law Firms
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0328042901&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Adam Poff
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0418716101&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Pilar Kraman
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, YOUNG, CONWAY, STARGATT & TAYLOR LLP, Wilmington, Delaware; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0321330201&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
James Haley
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, HALEY GUILIANO LLP, New York, New York; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0422106701&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Jason Fowler
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, COVINGTON & BURLING LLP, Washington, District of Columbia, Counsel for Plaintiff ChromaDex, Inc.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0328042901&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Adam Poff
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0418716101&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Pilar Kraman
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, YOUNG, CONWAY, STARGATT & TAYLOR LLP, Wilmington, Delaware; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0321330201&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
James Haley
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, HALEY GUILIANO LLP, New York, New York, Counsel for Plaintiff Trustees of Dartmouth College.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0418029101&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Andrew Mayo
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, ASHBY & GEDDES P.A., Wilmington, Delaware; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0165715701&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Donald Ware
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0306143001&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Jeremy Younkin
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0357400401&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Marco Quina
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0192318101&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Peter Ellis
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0506093701&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Urszula Nowak
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, FOLEY HOAG LLP, Boston, Massachusetts, Counsel for Defendant.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf18 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_opinion_26}{\*\bkmkend co_opinion_26}
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4dd92c721d4511ecac2eeffc2c51f}{\*\bkmkend co_anchor_I4dd92c721d4511ecac2eeffc2c51f}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4de22d211d4511ecac2eeffc2c51f}{\*\bkmkend co_anchor_I4de22d211d4511ecac2eeffc2c51f}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4de22d211d4511ecac2eeffc2c51f}{\*\bkmkend co_anchor_I4de22d211d4511ecac2eeffc2c51f}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa200 \sb800 
MEMORANDUM OPINION
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0511148701&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
COLM F. CONNOLLY
}}}
\sa200 
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
, CHIEF JUDGE
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_1_26}{\*\bkmkend co_pp_sp_999_1_26}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Plaintiffs ChromaDex, Inc. and Trustees of Dartmouth College (collectively, ChromaDex) have sued Defendant Elysium Health, Inc. for infringement of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027880005&pubNum=0004074&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=PA&docFamilyGuid=Ia5445800b4b711e1aa61b5a74a43ad52&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent Numbers 8,197,807 (the #807 patent)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 8,383,086 (the #086 patent). Pending before me is Elysium Health\rquote s Motion for Summary Judgment (No. 1) of Invalidity Under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. D.I. 182. Elysium argues that claims 1, 2, and 3 of the #807 patent and claim 2 of the #086 patent are invalid under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 for claiming patent-ineligible subject matter.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4de317811d4511ecac2eeffc2c51f}{\*\bkmkend co_anchor_I4de317811d4511ecac2eeffc2c51f}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4de317811d4511ecac2eeffc2c51f}{\*\bkmkend co_anchor_I4de317811d4511ecac2eeffc2c51f}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
I. BACKGROUND
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The asserted patents claim compositions containing isolated nicotinamide riboside (NR), a naturally occurring form of vitamin B3. Isolated NR facilitates production of \u8220\'3fNAD
}
{\b0 \cf1 \f2 \i0 \fs16 
{\super \b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
+
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
,\u8221\'3f a coenzyme associated with various biological activities.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The asserted claims of the #807 patent read as follows:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
1. A composition comprising isolated nicotinamide riboside in combination with one or more of tryptophan, nicotinic 60 acid, or nicotinamide, wherein said combination is in admixture with a carrier comprising a sugar, starch, cellulose, powdered tragacanth, malt, gelatin, talc, cocoa butter, suppository wax, oil, glycol, polyol, ester, agar, buffering agent, alginic acid, isotonic saline, Ringer\rquote s solution, ethyl alcohol, poly- 65 ester, polycarbonate, or polyanhydride, wherein said composition is formulated for oral administration and increases NAD+ biosynthesis upon oral administration.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
2. The composition of claim 1, wherein the nicotinamide riboside is isolated from a natural or synthetic source.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
3. The composition of claim 1, wherein the formulation comprises a tablet, troche, capsule, elixir, suspension, syrup, wafer, chewing gum, or food.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
#807 patent at claims 1\u8211\'3f3.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Asserted claim 2 of the #086 patent depends from independent claim 1, which is not asserted.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00012054542852_ID0E4GAC_26}{\*\bkmkend co_fnRef_B00012054542852_ID0E4GAC_26}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00012054542852_26" }{\fldrslt 
{\super \b0 \cf23 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
1
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Those two claims read as follows:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
1. A pharmaceutical composition comprising nicotinamide riboside in admixture with a carrier, wherein said composition is formulated for oral administration.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
2. The pharmaceutical composition of claim 1, wherein the nicotinamide riboside is isolated from a natural or synthetic source.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
#086 patent at claims 1, 2. I have construed the phrase \u8220\'3fpharmaceutical composition\u8221\'3f to mean \u8220\'3fa composition that can be used to improve or prolong the health or well-being of humans or other animals.\u8221\'3f D.I. 152 at 3.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4de784511d4511ecac2eeffc2c51f}{\*\bkmkend co_anchor_I4de784511d4511ecac2eeffc2c51f}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4de784511d4511ecac2eeffc2c51f}{\*\bkmkend co_anchor_I4de784511d4511ecac2eeffc2c51f}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
II. LEGAL STANDARDS
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4de784511d4511ecac2eeffc2c51f}{\*\bkmkend co_anchor_I4de784511d4511ecac2eeffc2c51f}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
A. Summary Judgment
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
A court must grant summary judgment \u8220\'3fif the movant shows that there is no genuine dispute as to any material fact and the movant is entitled to judgment as a matter of law.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR56&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Fed. R. Civ. P. 56(a)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Material facts are those \u8220\'3fthat could affect the outcome\u8221\'3f of the proceeding. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2024722701&pubNum=0000506&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RP&fi=co_pp_sp_506_181&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_181" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Lamont v. New Jersey
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 637 F.3d 177, 181 (3d Cir. 2011)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. \u8220\'3f[A] dispute about a material fact is genuine if the evidence is sufficient to permit a reasonable jury to return a verdict for the non-moving party.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (internal quotation marks omitted). A non-moving party asserting that a fact is genuinely disputed must support such an assertion by: \u8220\'3f(A) citing to particular parts of materials in the record, including depositions, documents, electronically stored information, affidavits or declarations, stipulations, ... admissions, interrogatory answers, or other materials; or (B) showing that the materials cited [by the opposing party] do not establish the absence ... of a genuine dispute ....\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR56&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Fed. R. Civ. P. 56(c)(1)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The non-moving party\rquote s evidence \u8220\'3fmust amount to more than a scintilla, but may amount to less (in the evaluation of the court) than a preponderance.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1989165175&pubNum=0000350&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RP&fi=co_pp_sp_350_460&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_460" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Williams v. Borough of West Chester, Pa.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 891 F.2d 458, 460\u8211\'3f61 (3d Cir. 1989)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4de8bcd11d4511ecac2eeffc2c51f}{\*\bkmkend co_anchor_I4de8bcd11d4511ecac2eeffc2c51f}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4de8bcd11d4511ecac2eeffc2c51f}{\*\bkmkend co_anchor_I4de8bcd11d4511ecac2eeffc2c51f}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
B. Patent-Eligible Subject Matter
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_2_26}{\*\bkmkend co_pp_sp_999_2_26}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*2
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Section
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 of the Patent Act defines patent-eligible subject matter. It provides: \u8220\'3fWhoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
There are three judicially created limitations on the literal words of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The Supreme Court has long held that laws of nature, natural phenomena, and abstract ideas are not patentable subject matter. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000780&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RP&fi=co_pp_sp_780_216&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_216" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice Corp. Pty. v. CLS Bank Int\rquote l
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 573 U.S. 208, 216 (2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. These exceptions to patentable subject matter arise from the concern that the monopolization of \u8220\'3fthese basic tools of scientific and technological work\u8221\'3f \u8220\'3fmight tend to impede innovation more than it would tend to promote it.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (internal quotation marks and citations omitted).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8220\'3fA claim to otherwise statutory subject matter does not become ineligible simply because it recites a natural law,\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2047911688&pubNum=0006538&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RP&fi=co_pp_sp_6538_1018&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_6538_1018" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic Foundation v. True Health Diagnostics LLC
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 760 Fed. App\rquote x 1013, 1018 (Fed. Cir. 2019)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, since \u8220\'3fall inventions at some level embody, use, reflect, rest upon, or apply laws of nature, natural phenomena, or abstract ideas.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RP&fi=co_pp_sp_780_71&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_71" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo Collaborative Servs. v. Prometheus Lab\rquote ys, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. 66, 71 (2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. But in order \u8220\'3fto transform an unpatentable law of nature [or natural phenomena] into a patent-eligible application of such law [or natural phenomena], one must do more than simply state the law of nature [or natural phenomena] while adding the words \u8216\'3fapply it.\u8217\'3f \u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (emphasis omitted).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the Supreme Court established a two-step framework by which courts are to distinguish patents that claim eligible subject matter under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 from patents that do not claim eligible subject matter under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The court must first determine whether the patent\rquote s claims are drawn to a patent-ineligible concept\u8212\'3fi.e., are the claims directed to a law of nature, natural phenomenon, or abstract idea? 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000780&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RP&fi=co_pp_sp_780_217&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_217" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 573 U.S. at 217
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. If the answer to this question is no, then the patent is not invalid for teaching ineligible subject matter. If the answer to this question is yes, then the court must proceed to step two, where it considers \u8220\'3fthe elements of each claim both individually and as an ordered combination\u8221\'3f to determine if there is an \u8220\'3finventive concept\u8212\'3f
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
i.e.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, an element or combination of elements that is sufficient to ensure that the patent in practice amounts to significantly more than a patent upon the [ineligible concept] itself.\u8221\'3f
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000780&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RP&fi=co_pp_sp_780_217&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_217" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 217\u8211\'3f18
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (alteration in original) (internal quotations and citations omitted).
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00022054542852_ID0EEHAE_26}{\*\bkmkend co_fnRef_B00022054542852_ID0EEHAE_26}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00022054542852_26" }{\fldrslt 
{\super \b0 \cf23 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
2
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_3_26}{\*\bkmkend co_pp_sp_999_3_26}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*3
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Issued patents are presumed to be valid, but this presumption is rebuttable. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2025432402&pubNum=0000780&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RP&fi=co_pp_sp_780_96&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_96" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Microsoft Corp. v. i4i Ltd. Partnership
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 564 U.S. 91, 96 (2011)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Subject-matter eligibility is a matter of law, but underlying facts must be shown by clear and convincing evidence. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043776259&pubNum=0000506&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RP&fi=co_pp_sp_506_1368&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1368" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Berkheimer v. HP Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 881 F.3d 1360, 1368 (Fed. Cir. 2018)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4dec8d611d4511ecac2eeffc2c51f}{\*\bkmkend co_anchor_I4dec8d611d4511ecac2eeffc2c51f}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4dec8d611d4511ecac2eeffc2c51f}{\*\bkmkend co_anchor_I4dec8d611d4511ecac2eeffc2c51f}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
III. DISCUSSION
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Applying the two-step framework from 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, I find that the asserted patent claims are invalid under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4decdb811d4511ecac2eeffc2c51f}{\*\bkmkend co_anchor_I4decdb811d4511ecac2eeffc2c51f}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4decdb811d4511ecac2eeffc2c51f}{\*\bkmkend co_anchor_I4decdb811d4511ecac2eeffc2c51f}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
A. 
}
{\b1 \cf1 \f2 \i1 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
 Step One
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8220\'3f[C]laims are considered in their entirety [at step one] to ascertain whether their character as a whole is directed to excluded subject matter.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036525254&pubNum=0000506&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RP&fi=co_pp_sp_506_1346&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1346" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Internet Patents Corp. v. Active Network, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 790 F.3d 1343, 1346 (Fed. Cir. 2015)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Elysium argues in its briefing that the asserted claims are directed to \u8220\'3fcompositions comprising isolated nicotinamide riboside (\u8220\'3fNR\u8221\'3f)[,] ... a naturally-occurring vitamin present in cow milk.\u8221\'3f D.I. 183 at 1. ChromaDex does not dispute this description of the asserted claims\u8217\'3f subject matter. And Elysium\rquote s description of the claims\u8217\'3f subject matter is entirely consistent with the language of the claims and the patents\u8217\'3f shared written description. Accordingly, the asserted claims are directed to a natural phenomenon.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
ChromaDex counters that \u8220\'3fthe mere fact that NR is found in nature does not establish that the claimed compositions are directed to patent-ineligible subject matter.\u8221\'3f D.I. 278 at 2. Quoting language from 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2047780027&pubNum=0000506&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Natural Alternatives International, Inc. v. Creative Compounds, LLC
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 918 F.3d 1338 (Fed. Cir. 2019)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, ChromaDex argues that the \u8220\'3fcorrect inquiry under 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 step 1 is ... whether compositions of the Asserted Claims \u8216\'3fhave different characteristics and can be used in a manner that [NR] as it appears in nature cannot.\u8217\'3f \u8221\'3f D.I. 278 at 3 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2047780027&pubNum=0000506&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RP&fi=co_pp_sp_506_1348&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1348" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Natural Alternatives
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 918 F.3d at 1348
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
) (alterations in the original). According to ChromaDex:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
The characteristics of the claimed compositions dramatically distinguish those compositions from naturally occurring NR. The claimed compositions contain isolated NR that is stable, bioavailable, and sufficiently pure that the compositions can be administered orally to deliver NR to the cells of an animal and exert therapeutic effect. Elysium\rquote s motion contains no showing that the NR in milk even reaches the bloodstream after the milk is consumed, let alone enters cells and provides therapeutic effect.
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
D.I. 278 at 6.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
But even if I were to apply the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 step one test as framed by ChromaDex, its argument fails. As an initial matter, the characteristics of the isolated NR in the claimed compositions that ChromaDex has identified as being different from the characteristics of NR in milk\u8212\'3fi.e., stability, bioavailability, sufficient purity, and therapeutic efficacy\u8212\'3fare immaterial to the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 inquiry because none of these characteristics are required by the claims. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2040082195&pubNum=0000506&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RP&fi=co_pp_sp_506_1149&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1149" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Synopsys, Inc. v. Mentor Graphics Corp.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 839 F.3d 1138, 1149 (Fed. Cir. 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fThe 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 inquiry must focus on the language of the Asserted Claims themselves.\u8221\'3f). Nothing in the language of the asserted claims or the patent\rquote s intrinsic evidence suggests that the claims require these characteristics. And, indeed, ChromaDex does not allege in its briefing that the claims impose such requirements. ChromaDex expressly states in its briefing that the asserted claims require that the recited compositions be capable of improving a patient\rquote s health and of enhancing NAD
}
{\b0 \cf1 \f2 \i0 \fs16 
{\super \b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
+
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 synthesis. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 D.I. 278 at 7 (stating that 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8220\'3fthe claims do require that the compositions have the capability to improve health and well-being (the [#]086 Patent) [and] enhance NAD
}
{\b0 \cf1 \f2 \i0 \fs16 
{\super \b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
+
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 biosynthesis (the [#] 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027880005&pubNum=0004074&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=PA&docFamilyGuid=Ia5445800b4b711e1aa61b5a74a43ad52&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
807 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
)\u8221\'3f). But those requirements have no bearing on the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 step one test articulated by ChromaDex, since it is undisputed that NR in milk improves health and well-being and enhances NAD
}
{\b0 \cf1 \f2 \i0 \fs16 
{\super \b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
+
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 biosynthesis, and thus those characteristics do not distinguish isolated NR in the claimed compositions from NR found in milk.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_4_26}{\*\bkmkend co_pp_sp_999_4_26}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*4
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The crux of ChromaDex\rquote s position seems to be that stability, bioavailability, purity, and therapeutic efficacy are implicitly required by the claims\u8217\'3f \u8220\'3fisolation\u8221\'3f limitation. ChromaDex states, for example, that \u8220\'3f[t]he use of isolated NR in the Asserted Claims requires that the NR in the claimed compositions be stable and bioavailable, allowing it to reach the bloodstream, enter the cell, and provide therapeutic effect.\u8221\'3f D.I. 278 at 4. And it argues that \u8220\'3f[b]ecause the NR in the claimed compositions is isolated\u8212\'3fand therefore stable, bioavailable, and pure\u8212\'3fthe claimed compositions can be used to deliver effective amounts of NR to cells.\u8221\'3f D.I. 278 at 6\u8211\'3f7. But the Supreme Court unanimously rejected this line of argument in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000780&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RP&fi=co_pp_sp_780_580&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_580" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Association for Molecular Pathology v. Myriad Genetics, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 569 U.S. 576, 580 (2013)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The Court held in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 that \u8220\'3fa naturally occurring DNA segment is a product of nature and not patent-eligible merely because it has been isolated.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 And it expressly rejected the argument that the asserted claims in that case were \u8220\'3fsaved by the fact that isolating DNA from the human genome severs chemical bonds and thereby creates a nonnaturally occurring molecule,\u8221\'3f because \u8220\'3fMyriad\rquote s claims are simply not expressed in terms of chemical composition, nor do they rely in any way on the chemical changes that result from the isolation of a particular section of DNA.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000780&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RP&fi=co_pp_sp_780_593&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_593" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 593
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In this case, the asserted claims are simply not expressed in terms of stability, bioavailability, or purity; nor do they rely in any way on changes that result from the isolation of NR. ChromaDex consented to my construction of \u8220\'3fisolated [NR]\u8221\'3f as NR \u8220\'3fthat is separated or substantially free from at least some of the other components associated with the source of the [NR].\u8221\'3f Tr. of Dec. 17, 2020 Hr\rquote g at 32:1\u8211\'3f6. And that construction in no way requires that the NR in the claimed composition be stable, bioavailable, sufficiently pure, or have a therapeutic effect.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Accordingly, I decline to import details not claimed and find that the asserted claims are directed to a natural product. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2047877778&pubNum=0000506&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RP&fi=co_pp_sp_506_769&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_769" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
ChargePoint, Inc. v. SemaConnect, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 920 F.3d 759, 769 (Fed. Cir. 2019)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (focusing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 analysis on the asserted claims because \u8220\'3fthe specification cannot be used to import details from the specification if those details are not claimed.\u8221\'3f), 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
cert. denied
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2050230397&pubNum=0000708&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
140 S. Ct. 983 (2020)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4df1e4911d4511ecac2eeffc2c51f}{\*\bkmkend co_anchor_I4df1e4911d4511ecac2eeffc2c51f}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4df1e4911d4511ecac2eeffc2c51f}{\*\bkmkend co_anchor_I4df1e4911d4511ecac2eeffc2c51f}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
B. 
}
{\b1 \cf1 \f2 \i1 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
 Step Two
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Having found that the claims are directed to a product of nature, I consider next whether they contain an \u8220\'3f \u8216\'3finventive concept\u8217\'3f sufficient to \u8216\'3ftransform\u8217\'3f the claimed [ineligible concept] into a patent-eligible application.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000780&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RP&fi=co_pp_sp_780_221&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_221" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 573 U.S. at 221
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RP&fi=co_pp_sp_780_77&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_77" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 77
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). It is insufficient for the patent to \u8220\'3fsimply state the law of nature while adding the words \u8216\'3fapply it.\u8217\'3f \u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RP&fi=co_pp_sp_780_72&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_72" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 72
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. A claim directed towards a natural product must include \u8220\'3fadditional features to ensure that the claim is more than a drafting effort designed to monopolize the [natural product].\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000780&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RP&fi=co_pp_sp_780_221&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_221" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 573 U.S. at 221
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quotation marks and alterations omitted) (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RP&fi=co_pp_sp_780_77&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_77" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 77
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
There are no such additional features here. The patents\u8217\'3f shared written description acknowledges, and ChromaDex does not dispute, that compositions containing NR \u8220\'3fcan be prepared by methods and contain carriers which are well-known in the art.\u8221\'3f #807 patent at 29:24\u8211\'3f
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; #086 patent at 28:49\u8211\'3f60. Nor does ChromaDex dispute that the physical act of isolating NR is not an inventive concept. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 #807 patent at 27:45\u8211\'3f54 (\u8220\'3fIsolated extracts of the natural sources can be prepared using standard methods.\u8221\'3f); #086 patent at 27:3\u8211\'3f12 (same); D.I. 292-1, Ex. 1 \u182\'3f 164 (ChromaDex\rquote s expert stating that \u8220\'3f[i]t is not the specific techniques of isolation that transform the Asserted Claims beyond a law of nature or natural phenomenon\u8221\'3f); 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000780&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RP&fi=co_pp_sp_780_591&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_591" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 569 U.S. at 591, 595
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (stating that \u8220\'3fthe processes used by Myriad to isolate DNA were well understood by geneticists at the time of Myriad\rquote s patents\u8221\'3f and that \u8220\'3fseparating th[e] [BRCA1 or BRCA2] gene from its surrounding genetic material is not an act of invention\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
ChromaDex argues initially in its briefing that the \u8220\'3finventive step\u8221\'3f of the asserted claims is the \u8220\'3frecogni[tion] [of] the utility of NR for enhancing health and well-being.\u8221\'3f D.I. 278 at 9. But \u8220\'3f[t]he inventive concept necessary at step 2 of the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo/Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 analysis cannot be furnished by [an] unpatentable law of nature (or natural phenomenon or abstract idea).\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038639328&pubNum=0000506&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RP&fi=co_pp_sp_506_1376&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1376" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Genetic Techs. Ltd. v. Merial L.L.C.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 818 F.3d 1369, 1376 (Fed. Cir. 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Perhaps because it realized the futility of its argument, ChromaDex abandoned it in the very next paragraph of its brief, stating there that \u8220\'3f[t]he inventive concept of the Asserted Claims is not the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
discovery
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 of the NR vitamin pathway, but rather therapeutic 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
applications
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 of this discovery in inventive ways beyond that of the prior art.\u8221\'3f D.I. 278 at 9\u8211\'3f10 (emphasis in the original). Its expert agrees with this latter position. In the expert\rquote s words:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_5_26}{\*\bkmkend co_pp_sp_999_5_26}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*5
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 [T]he inventive concept is the pioneering decision to create a composition comprising isolated NR formulated for oral administration. This was not well-understood, routine, and conventional activity at the time of the invention; ... it was not until [the inventor] Dr. Brenner\rquote s work in 2004 that the scientific community even became aware of the importance of NR as an orally available vitamin or what it would do in the body.
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
D.I. 292-1, Ex.1 \u182\'3f 164.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
This revised articulation of the putative inventive concept fails too. Because NR\rquote s oral bioavailability is an inherent property of NR and thus is itself a natural phenomenon, ChromaDex did not alter NR to create this property. It simply uncovered it. ChromaDex is essentially arguing that the idea of making an oral formulation of NR was inventive. But the decision to create an oral formulation of NR after discovering that NR is orally bioavailable is simply applying a patent-ineligible law of nature. And the Supreme Court has made clear that more than \u8220\'3fapply it\u8221\'3f is needed to \u8220\'3ftransform an unpatentable law of nature into a patent-eligible application of such a law.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RP&fi=co_pp_sp_780_72&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_72" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 72
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
ChromaDex disagrees and cites the Federal Circuit\rquote s decision in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RP&fi=co_pp_sp_506_1050&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1050" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Rapid Litigation Management, Ltd. v. CellzDirect, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 827 F.3d 1042, 1050\u8211\'3f51 (Fed. Cir. 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 for the proposition that \u8220\'3fa claim that \u8216\'3fapplies the discovery\u8217\'3f to achieve something new and useful suffices to provide an inventive concept.\u8221\'3f D.I. 278 at 10 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RP&fi=co_pp_sp_506_1050&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1050" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
CellzDirect
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 827 F.3d at 1050\u8211\'3f51
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). But the Court in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
CellzDirect
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 stressed that the patent-eligible asserted claims at issue in that case were 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8220\'3fdirected to a new and useful method,\u8221\'3f as opposed to a product claim. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RP&fi=co_pp_sp_506_1048&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1048" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
827 F.3d at 1048\u8211\'3f49
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (noting that the asserted claims \u8220\'3fare like thousands of others that recite 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
processes
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to achieve a desired outcome, e.g., 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
methods
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 of producing things or, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
methods
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 of treating diseases\u8221\'3f) (emphasis added)); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RP&fi=co_pp_sp_506_1049&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1049" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1049
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (stating \u8220\'3fthe claims are directed to a new and useful process of creating [the] pool [of cells], not to the pool [of cells] itself); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RP&fi=co_pp_sp_506_1049&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1049" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1049
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (stating that the method claims before it were \u8220\'3fdistinguishable from [the composition claims] held unpatentable in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8221\'3f). The asserted claims here are composition claims, and thus they are governed by 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad. See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000780&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RP&fi=co_pp_sp_780_595&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_595" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 569 U.S. at 595
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (noting that the claims the Court found to be patent-ineligible were not method claims purporting to create an inventive method of manipulating genes).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4df678711d4511ecac2eeffc2c51f}{\*\bkmkend co_anchor_I4df678711d4511ecac2eeffc2c51f}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4df678711d4511ecac2eeffc2c51f}{\*\bkmkend co_anchor_I4df678711d4511ecac2eeffc2c51f}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
IV. CONCLUSION
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
For the reasons discussed above, I find that claims 1, 2, and 3 of the #807 patent and claim 2 of the #086 patent are invalid under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 for claiming patent-ineligible subject matter. Accordingly, I will grant Elysium\rquote s motion for summary judgment (D.I. 182).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Court will issue an Order consistent with this Memorandum Opinion.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf18 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_allCitations_26}{\*\bkmkend co_allCitations_26}
{\b1 \cf18 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
All Citations
\par 
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Slip Copy, 2021 WL 4286527
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 \par}\sect\sbknone\pgncont\cols1{\ids0 {
{\trowd \ltrrow \trleft0 
\clpadl200 \clpadfl3 \clbrdrt \clbrdrl \trql \clwWidth10080 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs20 \li0 
{\b0 \cf1 \f3 \i0 \fs20 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Footnotes
\par 
}
}
}
}\b0 \cf1 \f3 \ri0 \ul0 \strike0 \i0 \ql \li0 \fs20 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f3 \i0 \fs24 
{\*\bkmkstart co_footnote_B00012054542852_26}{\*\bkmkend co_footnote_B00012054542852_26}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00012054542852_ID0E4GAC_26" }{\fldrslt 
{\super \b0 \cf23 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
1
}\super \b0 \cf23 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f3 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
The Patent Trial and Appeal Board has already held that claim 1 of the #086 patent is invalid. 
}
{\b0 \cf1 \f3 \i1 \fs18 
{\b0 \cf1 \f3 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\b0 \cf1 \f3 \i1 \fs18 
{\b0 \cf1 \f3 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Elysium Health Inc. v. Trustees of Dartmouth College
}
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, No. IPR2017-01795, Paper No. 39 (P.T.A.B. Jan. 16, 2019), 
}
{\b0 \cf1 \f3 \i1 \fs18 
{\b0 \cf1 \f3 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
aff\rquote d
}
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2050524657&pubNum=0006538&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
796 Fed. App\rquote x 745 (Fed. Cir. 2020)
}\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
.
\par 
}
}
}
}
}\b0 \cf1 \f3 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \lastrow \trleft0 
\clbrdrb \clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrb \clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f3 \i0 \fs24 
{\*\bkmkstart co_footnote_B00022054542852_26}{\*\bkmkend co_footnote_B00022054542852_26}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00022054542852_ID0EEHAE_26" }{\fldrslt 
{\super \b0 \cf23 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
2
}\super \b0 \cf23 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f3 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
The Court in 
}
{\b0 \cf1 \f3 \i1 \fs18 
{\b0 \cf1 \f3 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 literally said that this two-step framework is \u8220\'3ffor distinguishing patents that claim laws of nature, natural phenomena, and abstract ideas from those that claim patent-eligible applications of those concepts.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000780&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=RP&fi=co_pp_sp_780_217&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_217" }{\fldrslt 
{\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
573 U.S. at 217
}\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
. But as a matter of logic, I do not see how the first step of the 
}
{\b0 \cf1 \f3 \i1 \fs18 
{\b0 \cf1 \f3 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Alice/Mayo
}
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 framework can distinguish (or even help to distinguish) patents in terms of these two categories (i.e., the categories of (1) \u8220\'3fpatents that claim laws of nature, natural phenomena, and abstract ideas\u8221\'3f and (2) patents \u8220\'3fthat claim patent-eligible applications of [laws of nature, natural phenomena, and abstract ideas]\u8221\'3f). 
}
{\b0 \cf1 \f3 \i1 \fs18 
{\b0 \cf1 \f3 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Both
}
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 categories 
}
{\b0 \cf1 \f3 \i1 \fs18 
{\b0 \cf1 \f3 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
by definition
}
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 claim laws of nature, natural phenomena, and abstract ideas; and only one of 
}
{\b0 \cf1 \f3 \i1 \fs18 
{\b0 \cf1 \f3 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8217\'3fs steps (i.e., the second, \u8220\'3finventive concept\u8221\'3f step) could distinguish the two categories. I therefore understand 
}
{\b0 \cf1 \f3 \i1 \fs18 
{\b0 \cf1 \f3 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8217\'3fs two-step framework to be the framework by which courts are to distinguish patents that claim eligible subject matter under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f3 \i0 \fs18 \chcbpat24 
{\b1 \cf19 \f3 \i0 \fs18 \chcbpat24 
{\b1 \cf19 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u167\'3f
}
}
}
{\b0 \cf23 \f3 \i0 \fs18 \chcbpat2 
}
{\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\b1 \cf19 \f3 \i0 \fs18 \chcbpat24 
{\b1 \cf19 \f3 \i0 \fs18 \chcbpat24 
{\b1 \cf19 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
101
}
}
}
{\b0 \cf23 \f3 \i0 \fs18 \chcbpat2 
}\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \chcbpat2 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 from patents that do not claim eligible subject matter under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I434851301b7111ec8b1bdba4dd95a23d&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f3 \i0 \fs18 \chcbpat24 
{\b1 \cf19 \f3 \i0 \fs18 \chcbpat24 
{\b1 \cf19 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u167\'3f
}
}
}
{\b0 \cf23 \f3 \i0 \fs18 \chcbpat2 
}
{\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\b1 \cf19 \f3 \i0 \fs18 \chcbpat24 
{\b1 \cf19 \f3 \i0 \fs18 \chcbpat24 
{\b1 \cf19 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
101
}
}
}
{\b0 \cf23 \f3 \i0 \fs18 \chcbpat2 
}\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \chcbpat2 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
.
\par 
}
}
}
}
}\b0 \cf1 \f3 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }}\par 
}
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 \par}\sect\sbknone\pgncont\cols1{\ids0 {
{\trowd \lastrow \trleft0 
\clpadt24 \clpadft3 \clpadl100 \clpadfl3 \clpadr24 \clpadfr3 \clbrdrt \brdrcf25 \brdrw10 \brdrs \clbrdrb \clbrdrl \trql \clvertalt \clwWidth4320 \cellx4320 
\clpadt29 \clpadft3 \clpadl100 \clpadfl3 \clpadr29 \clpadfr3 \clbrdrt \brdrcf25 \brdrw10 \brdrs \clbrdrb \clbrdrr \trql \clvertalt \clwWidth5760 \cellx10080 
\intbl 
{\ri24 \li24 
{\b1 \cf25 \f3 \ri24 \i0 \ql \fs16 \li24 
{\b1 \cf25 \f3 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
End of Document
\par 
}
}
}\b1 \cf25 \f3 \ri24 \ul0 \strike0 \i0 \ql \li24 \fs16 \sa0 \sb0 \intbl \cell \intbl 
{\ri29 \li29 
{\qr \b0 \cf25 \f3 \ri29 \i0 \fs19 \li29 
{\b0 \cf25 \f3 \ul0 \strike0 \i0 \fs19 \sa0 \sb0 
\u169\'3f 2021 Thomson Reuters. No claim to original U.S. Government Works.
\par 
}
}
}\qr \b0 \cf25 \f3 \ri29 \ul0 \strike0 \i0 \li29 \fs19 \sa0 \sb0 \intbl \cell \row }}\par 
}
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}\sect }